| Description |
Enfumafungin, a triterpene glycoside, is isolated from extracts derived from an endophytic species of Hormonema. Enfumafungin is an antifungal compound that is acting on the fungal cell wall, as the (1,3)-beta-D-glucan synthase inhibitor. Enfumafungin is specific for yeasts and fungi (excluding Cryptococcus) and does not inhibit the growth of Bacillus subtilis[1][2].
|
| Related Catalog |
|
| Target |
(1,3)-beta-D-glucan synthase[1]
|
| In Vitro |
Enfumafungin (24-48 h) has MICs of less than 0.5 μg/mL against the Candida and Aspergillus species tested and it is inactive against Cryptococcus, including the decapsulated form (MY2062)[1].
|
| In Vivo |
Enfumafungin (50-200 mg/kg; i.p. twice daily for 2 days) produces a significant decrease in the number of c.f.u. in kidneys of mice challenged with C. albicans, with an ED90 of 90 mg/kg[1].
|
| References |
[1]. Peláez F, et, al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol. 2000 Oct;23(3):333-43. [2]. Onishi J, et, al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000 Feb;44(2):368-77.
|
